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ABSTRACT 
 
The increase in treatment options for HIV positive people has contributed to an increase in the number 
of people willing to be tested for HIV since there are now tangible benefits associated with a confirmed 
HIV positive diagnosis. In Southern Africa the trend towards increased numbers of people who know 
their HIV status has been more noticeable in women than in men (Muula, et al., 2007), possibly due to 
the greater health seeking behaviour of women compared to men as well at the access that women have 
to HIV testing during pregnancy as part of countries‟ efforts towards preventing mother-to-child 
transmission of HIV. In Namibia there has been a massive increase in the number of patients 
commenced on antiretroviral therapy (ART) (MOHSS, 2007) .  
 
It is important to ensure that increases in the number of patients being started on treatment are 
accompanied by a proportional improvement in the quality of care being provided to the patients. One 
important concept that has been promoted in recent years is the Greater Involvement of People Living 
with HIV/AIDS (GIPA). This concept promotes the inclusion of HIV infected individuals in the 
decision making process when making decisions regarding the welfare of People Living With HIV 
(PLHIV). One important caveat specific to ART is the high levels of adherence required for sustained 
effectiveness of the medicines. Involvement of patients in the design of their treatment has been shown 
to be a facilitator of adherence to treatment. 
 
This study design was a cross-sectional survey whereby a sample of individuals who are registered at 
Oshakati Communicable Disease Clinic and were receiving ART were interviewed to determine who 
they perceived to have been the principal decision maker for them to be commenced on ART. The 
responses were categorized according to the responses from the patients and the frequencies calculated 
to find the percentage of the patients on ART who considered themselves to have been involved in the 
decision making process. Having the majority of the patients perceiving themselves as having not been 
involved in the decision making process was thought to have an important bearing on the counselling 
which was done prior to starting treatment. This can therefore inform initiatives to improve case 
management and the involvement of patients in designing their treatment regimens and in making 
important decisions about their treatment. This ultimately helps to improve the adherence of these 
patients to their treatment, thereby improving the treatment outcomes and reducing the rate of 
development of resistance to the antiretroviral medicines (ARVs).  
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OPSOMMING 
Agtergrond 
Die verhoging in die behandeling opsies vir MIV positiewe mense het bygedra tot n verhoogde syfers 
van die mense gewillig om getoets te word vir MIV, omdat daar voordele is geassosiaseer met die 
bevestige MIV positief diagonose. In Suider Afrika die patron teen die verhoogde syfers of mense wat 
hulle MIV status ken is meer gekenmerk in vroumense as mans, dit is moontlik weens dat die  
vroumense hul gedrag teenoor  gesondheid raadpleging goed is in vergeluking met die mans, en die 
vroumense het toegang aan MIV toetse gedurende die swangerskap periode as deel van die land se 
poging vir die voorkoming van moeder tot kind transmissie of MIV. In Namibie is daar n geweldige 
verhoogde syfers in pasiente wat met die MIV behandel/therapie begin (ART) het. Die verhoogde 
syfers of pasiente wat op behandel begin is moet vergesel word met  n proposie van verbetering in 
kwaliteit sorg voorsien aan pasiente. Een van die belangrikste konsepte wat gedurende afgelope jare 
bevorder is die Betrokkenheid van Mense Leef met MIV wat aanmoedig dat die individuele mense wat 
met MIV  Leef ingesluit word in besluitnemings. Betrokkenheid van pasiente in die gebruik van hulle 
behandeling is n bewys van hulle toewyding tot hulle behandeling. 
 
Studie  Metode 
Die studie uitleg was n cross-sectional ondersoek waar geregistrede individuele by Oshakati 
Communicable Disease Clinic, wie MIV behandeling ontvang was ondervra om vas te stel wie was 
hulle hoof besuitnemer vir hulle om met hierdie MIV behandeling te begin. Die terugvoering is 
gekategoriseer volgens die bevindings van die pasiente oor hulle betrokkenheid en die besluitneming 
van hulle behandeling. 
 
Uitslae 
Die meerderheid van die pasiente (83%) het  terugvoering gegee dat hulle tot n sekere matte in die 
besluitneming omtrent hulle behandeling betrokke was dit geld vir mans en vroumense. 
Afsluiting 
Die meederheid van die pasiente neem aan dat hulle betrokke is in die proses van die besluitneming, 
wat n positiewe invloed op die toewydig tot hulle medikasie het; en stel voor dat daar wel berading vir 
pasiente gegee word voor hulle met behandeling begin. 
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1. INTRODUCTION 
1.1. Epidemiology of HIV in Namibia 
Just like the rest of Southern Africa, Namibia has a generalized HIV epidemic. The first case of 
HIV infection was reported in Namibia in 1986 (MOHSS, 2008). The country is among the 
worst affected in the world with an antenatal seroprevalence rate of 17.8% in 2008 with no 
notable difference between rural and urban areas (MOHSS, 2008). This represents a slight but 
notable decline from the 2002 peak of 22%. The antenatal sero-prevalence survey is currently the 
major source of prevalence data in the country, in the absence of population prevalence surveys. 
The number of people who were living with HIV  in 2008 was estimated to be 204,000 while by 
2012/13 this value was predicted to be about 247,000 people.  “Despite stabilizing HIV 
prevalence, the number of people living with HIV will continue to increase as the total 
population size in that age range grows” (MOHSS, 2008). Unlike in the western world where the 
epidemic predominantly affects males, about 58% of those living with HIV in Namibia in 
2007/08 are women, with women also being infected at a slightly younger age than men 
(MOHSS). 
 
Public health care facilities began providing antiretroviral therapy (ART) in 2003 and voluntary 
counselling and testing (VCT) services in 2004, and since then there has been remarkable 
expansion in the coverage of these interventions (MOHSS). The advent of ART has seen more 
and more people volunteering to be tested for HIV since there are now tangible benefits 
associated with knowledge of one‟s HIV status. Despite this increase in the number of patients 
being tested however, HIV testing rates among males remain significantly lower than those of 
females. This has been partly attributed to the lower health care seeking behaviour in males 
compared to that in females, as it has been found that “men are less likely to seek health care 
than women” (UNAIDS, 2000) and for those that do seek health care “older men frequently 
delay seeking health care for illnesses that could be prevented or cured”  (UNAIDS). These 
general trends of men‟s fewer contacts with health care workers are well documented 
internationally and as much as “eight out of ten men admit to waiting too long before going to 
see their doctor” (MHFI, 2004). This may be due to various socio-cultural factors and the real 
threat to their financial stability since men may be afraid of losing their jobs if they are known to 
be HIV positive (WHO, 2003). 
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Figure 1: Trends in antenatal HIV prevalence rates in Namibia; 1992-2008 
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When HIV positive patients are enrolled into public care facilities they are usually managed 
according to standardized protocols. In Namibia follow-up schedules for HIV infected patients at 
the time of the study were based on their World Health Organisation (WHO) clinical stage as 
well as the CD4 count, and whether the patient was on ART or not. The clinical stage was used 
as it gave a qualitative measure of the extent to which the patient‟s immune system has been 
damaged by HIV as indicated by the type of opportunistic infections (diseases which afflict 
patients with impaired immune systems) that the patient presents with, while the CD4 count gave 
a quantitative measure of this immune destruction since the CD4 cells (a subset of the white 
blood cells responsible for controlling the body‟s defense against infection) are the primary 
target of destruction by HIV.  
The country‟s 2007 version of the National Guidelines for Antiretroviral Therapy has the 
following as the eligibility criteria for commencing HIV positive adult and adolescents on ART: 
 WHO Clinical stage 3 and 4 disease, irrespective of CD4 cell count, or 
 CD4 count less than 200 cells/mm3 (less than 250 cells/mm3 in pregnant women) 
irrespective of WHO clinical stage, and  
 Met social eligibility criteria. The social criteria included are that the patient must: 
o Have lived at a fixed address for the previous 3 months, 
o Have ready access to a designated treatment centre for follow-up, 
o Not drink alcohol, 
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o Have no untreated underlying psychiatric disorders, 
o Be committed to: 
 Lifelong treatment with ART 
 Practising safe sex, and 
 Allowing home visits if indicated (MOHSS, 2007) 
 
As ART continued to be rolled out, many programmes were now battling to improve the 
treatment outcomes among patients commenced on treatment. One of the key requirements for 
the success of currently available ART is a high degree of adherence to the treatment. Very high 
levels of adherence are required to ensure durable suppression of the virus in the blood which 
will in turn maximize the chances of treatment success and prevent the development of resistance 
of the HIV to the antiretroviral drugs. Successful treatment also meant that the patient would 
remain free of the many opportunistic infections that frequently afflict HIV infected individuals. 
It should be noted however that as ART continues to be rolled out and more and more patients 
are commenced on treatment “the number of people dying of AIDS related causes will continue 
to grow… due to the increasing numbers of people on treatment who might default or have 
adverse reactions as well as the increasing ages of those on treatment” (MOHSS, 2008).  
 
Adherence levels for patients on chronic medication are usually suboptimal. Among patients on 
treatment for diabetes for example, “non-adherence to treatment is more the norm than the 
exception” (Rowley, 1999). While there are many factors which may be responsible for this, the 
health care system is considered to have an input into the levels of adherence to therapy amongst 
patients on HAART. Health care provider related factors such as accessibility, cost, drug stock 
out, lack of expertise and lack of sensitivity to the needs of PLHIV can all potentially have an 
impact on adherence. One factor that is commonly cited as a potential cause of adherence 
problems is a treatment plan that fails to fit into the lifestyle of the patient. This is often a result 
of the failure of the health care system to explore the individual patient‟s social perspectives and 
come up with interventions that are tailor-made to the patient‟s needs. 
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Oshakati Communicable Disease Clinic is a hospital based public HIV care clinic in the Oshana 
Region of northern Namibia. At the time of the study it was the largest HIV clinic in the country 
with over 12000 registered patients as of July 2008. The clinic offered services to all HIV 
positive patients whether they currently required HAART or not. Patients who were on treatment 
were given follow-up schedules based on their duration on treatment and any co-morbidities 
(other coexisting diseases), while patients who were not yet on treatment and who did not have 
any other co-existing conditions requiring regular follow-up were given a six-monthly follow up 
schedule according to the Namibia‟s National Guidelines for Antiretroviral Therapy (MOHSS). 
 
Figure 2: Map of Namibia showing the location of Oshakati (shown by the red asterix) 
 
 
Oshakati 
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1.2. Justification for the Study 
The level of patient involvement in the decision making process had not been evaluated for 
patients in chronic HIV care in Namibia. The massive scale up of anti-retroviral therapy 
coverage had resulted in a very large number of patients registering for HIV care and being 
started on ART. Due to pressure in the clinics brought about by these large patient volumes it 
was possible that there was not enough time in the HIV care clinics to discuss the treatment 
adequately with each individual patient to ensure that they fully comprehended the requirements 
of their treatment. Anecdotally this had the potential to have a domino effect as more and more 
patients were started on treatment since some of the approaches which may have been adopted to 
cope with the high patient numbers (the so-called „short-cuts‟) became systematized and adopted 
as standard practice since they appeared to be “working”. Thus as the country shifted focus from 
coverage to also include quality of service provided to the patients it was important to involve 
the patients in the decision making processes regarding how they were managed. To put 
measures in place to improve patient involvement in the decision making process required a 
baseline assessment of the current levels of patient involvement in this process. One initial step 
in this direction was therefore to determine the patients‟ current perceived levels of involvement 
in the decision to start ART. 
 
This study sought to investigate the perceived involvement of patients in the decision to start 
ART. This was done by interviewing patients who were already on treatment to find out if they 
considered themselves to have been involved in the decision to start treatment. Patients who 
were already on treatment were the study population for the study. Low levels of perceived 
patient involvement in the decision making process was considered a pointer to the need for 
training of health workers to involve patients in the decision making process. This is because 
patients‟ involvement in major decisions regarding their treatment was thought to have a 
significant bearing on adherence to treatment.  
1.3.Background of the problem     
The developments in the field of anti-retroviral therapy have brought significant benefits to 
patients and their families as well as large corporations. This is because they have transformed 
HIV/AIDS from an incurable affliction to a manageable chronic illness and has resulted in 
decreased morbidity and mortality. In Namibia for example, 93% of patients enrolled into the 
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public ART programme were alive four years after the programme started (MOHSS). With the 
current treatments, however, the treatment is still life long since there is as yet no proven cure for 
HIV infection. This lifelong treatment is a major challenge for patients, especially because of the 
stringent adherence requirements demanded for successful therapy. The National Guidelines for 
Antiretroviral Therapy among other publications say that the patient needs to take at least 95% 
of the prescribed medicine doses to maintain enough levels of the medicines in the blood to 
achieve sustained viral suppression, with lower levels of adherence promoting the development 
of resistance to the treatment (MOHSS). “Knowing that HAART is a lifelong commitment, it is 
the duty of all stakeholders- including family, friends, employers and other partners- to render 
support to HIV/AIDS patients to comply with treatment. Failure to do so will result in the 
development of ARV resistant HIV strains with dire consequences…” (MOHSS). Development 
of resistance to ARVs is major a public health concern because there is a possibility of drug 
resistant viruses spreading to other people in the community, especially if HIV prevention 
messages and interventions are not integrated into the care and treatment protocols. Adherence to 
ART is made more difficult by the fact that the patients on ART have to continue seeking 
medical attention long after their symptoms have improved following successful recovery of the 
immune system.  
 
While the national guidelines are clear on which patients were considered eligible to start 
treatment, implementation of these guidelines and the role the patient should play in the decision 
to start treatment were not as clearly defined. For this reason there was likely to be great 
variability in the extent to which patients are involved in the process based on the approaches of 
individual clinicians. This lack of uniformity could create potential challenges for patients when 
they moved from one clinic to another as they would have different expectations of the health 
care system. It is therefore important to ensure that the entire national programme is striving 
towards a high degree of patient involvement in at least the major decisions regarding their 
treatment 
 
The 2007 Namibian guidelines recommended repeating the CD4 count test for patients who were 
not yet on treatment every six months, and this also tended to be the follow-up interval for these 
patients since it was deemed unnecessary for them to come before their blood work-up was due. 
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This did not seem to take into account the additional psychosocial as well as other individual 
needs of PLHIV as acknowledged by the Namibian technical guidelines; “Follow-up counselling 
of the patient and review of his/her environment to ensure continued psychosocial support and to 
enhance adherence to treatment” is a prerequisite for provision of ART (MOHSS). These needs 
are not uniform among the patients and require a careful empathetic assessment and discussions 
with the patient to decipher the different needs of each patient. This usually requires more than 
one clinic visit, and the dynamism of the different stages of psychological evolution following an 
HIV positive diagnosis also need to be taken onto account. 
 
“Despite all efforts that have gone into prevention and care, active participation of men in all of 
these (HIV treatment and prevention) programmes is lagging behind” with 64% of the patients 
on ART in Namibia being women (MOHSS). This observation underscores the problems 
associated with the generally acknowledged lower health seeking behavior in men in sub-
Saharan Africa when compared to their female counterparts. Association between gender and the 
level of involvement in treatment decisions regarding ART has not been systematically studied 
in Namibia. The current practice in clinics does not specifically differentiate between genders in 
the approach to preparing the patient for treatment. 
1.4. Statement of the problem 
The 2007 technical guidelines for following up HIV infected patients and initiating them on ART 
are mainly based on medical criteria. Social criteria were included in the guidelines for Namibia 
as highlighted above so as to try and eliminate potential inhibitors of adherence to treatment. 
However the implementation of these guidelines and the involvement of the patients in the 
decision making process were not being routinely assessed using the existing monitoring and 
evaluation tools. It was therefore necessary to conduct this study so as to try and determine the 
extent to which the patients currently on treatment were involved in the decision to start them on 
treatment. This could then be used as a proxy to measure the involvement of the patient in the 
overall decision making process.  
There are also fundamental differences in health seeking behavior between men and women and 
this can have a significant bearing on the desired frequency of contact with health care workers. 
The fact that traditionally men are the decision makers in most sub-Saharan African communities  
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(Muula, et al., 2007) may potentially influence the decision making process regarding ART, with 
female patients being inclined to allow the (often male) doctors to make decisions about their 
treatment. The analysis will include comparing the decision making process by gender and this 
will then help in the development of gender specific interventions if there is a significant 
difference between males and females. These issues needed to be evaluated and have their 
significance validated, and this study sought to provide information in this regard.  
1.5.Significance of the study  
The acceptability and desirability of the services that are offered to HIV infected patients were 
not being routinely evaluated in clinical practice in the country. Outcome measures such as the 
number of deaths averted and the reduction in morbidity are often cited as the major 
achievements of ART. There is however need to create more patient oriented services, with the 
views and preferences of patients being taken into account. The study aimed at trying to outline 
and highlight the level of variability in patient experiences as far as the role which they played in 
the decision to start treatment was concerned.  
1.6.Scope of the study 
The study sought to assess patients who were on ART, and it only evaluated those patients 
enrolled in care. It focused only on the adult patients (18-70 years of age) who were already on 
treatment (ART) and who were otherwise capable of making their own decisions. The study was 
confined to one clinic only and assessed the patients already enrolled into care. As such the 
results of the study are only applicable to that clinic and are not generalisable to other clinics in 
the country.             
1.7.Purpose of the study     
The study intended to investigate the patients‟ experiences as far as the decision to start them on 
antiretroviral therapy was concerned. It mainly sought to determine who, from their point of 
view, was responsible for making the decision to start them on treatment. The study also sought 
to investigate whether there were significant differences in the patients‟ experiences during 
initiation of treatment. Significant variability among the patients could suggest a difference 
among the various clinicians who came into contact with the patients, whereas minimal 
variability could be a reflection of the organizational issues relating to patient management. This 
would be very important when reviewing patient management approaches since the patient‟s 
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involvement in their own care has been shown to have an impact on the patient‟s adherence to 
treatment. Thus a finding of 90% of the patients not being involved in the decision to start them 
on treatment could necessitate that the protocols and standard operating procedures be revised to 
enhance more patient involvement in the decision making process; whereas a finding of 40% of 
patients being involved in the decision for them to start on treatment could suggest a potential 
problem of implementation of the protocols on the part of individual clinicians. 
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2. RESEARCH PROBLEM, OPERATIONALISATION & HYPOTHESIS 
2.1. Research Question 
The research problem which was studied and analysed was: 
Who do HIV positive adults on ART at Oshakati Hospital Communicable Disease 
Clinic perceive as the person who made the decision for them to start antiretroviral 
therapy? 
“HIV positive” in this study referred to those patients who had been tested and found to be HIV 
infected through either rapid HIV tests or through laboratory blood testing and had enrolled into 
chronic HIV care, while “adults” were those patients registered in the clinic who were aged 
eighteen years and above at the time that ART was initiated. “ART” refers to Antiretroviral 
Therapy, which is also sometimes simply referred to as combination antiretroviral therapy 
(cART) or highly active antiretroviral therapy (HAART). 
2.2. Hypotheses 
The scientific hypothesis was that the 75% of adult patients who are on HAART at Oshakati 
Hospital were not involved in the decision to start them on HAART, while the null hypothesis 
contended that the majority of the adult patients on HAART were involved in the decision to 
commence them on treatment.  
2.3. Research Objectives            
The objectives of the research were: 
 To find out the proportion of patients who were part of the decision making process when 
the decision for them to start them on treatment was made. 
 To evaluate if this proportion warrants an adjustments to the existing protocols to 
improve patient involvement in the decision to start treatment 
 To identify areas for future research in the field of patient-provider relationships in light 
of the ever changing scope of chronic HIV care. 
 
11 
 
2.4. Research Design 
The research design which was used for this study was a cross sectional  survey. This is a non-
experimental research technique which is often used to collect data from a representative sample 
of the study population. The interview technique was used to obtain data on the patients‟ 
experience concerning the decision that was made for them to be started on anti-retroviral 
therapy. The main challenge in this study design was to select a population that is representative 
enough of the study population.  
2.5. Population  
The research was carried out at Oshakati State Hospital Communicable Disease Clinic, which is 
the clinic that provides care to HIV positive patients in and around Oshakati. The clinic caters for 
patients who are eligible to be initiated on ART as well as those who are not yet eligible. The 
population under study was however confined to stable adult patients who were HIV positive and 
who had been started on ART according to the Namibian guidelines for ART eligibility. These 
were patients in whom the decision to initiate ART had already been made and are already taking 
their antiretroviral medicines.  
2.6. Sampling and Sample Size 
Systematic random sampling was used and patients already on treatment during the month of the 
study were selected. Children and patients deemed incapacitated to make their own decisions due 
to mental illness or severe disease were excluded from the study population. To safeguard 
against the potential pitfall of approaching patients who understood the language that the 
interviewer was comfortable since these would probably be interviewed faster, or to select 
patients of particular age groups due to the interviewer preferences, every second eligible patient 
was enrolled into the study. The sample size was calculated on the basis of an estimated 
population size of 6500 adult patients currently actively being followed up at the clinic, with a 
90% confidence level and a 5% confidence interval. A sample size calculator downloaded from 
www.macorr.com was used for the sample size calculation and the sample size was determined 
to be 261. A 95% confidence level would have been preferred but this was not possible due to 
time limitations since this would have increased the sample size to 363.  
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2.7. Data collection  
The selected patients were interviewed following a predesigned questionnaire (Annex 1) using 
the face to face method of data collection. The responses were then categorized and from these 
interviews the proportion of patients who were involved in the decision making process was 
calculated. There were three categories of responses: decision made by health worker, decision 
made by the health worker and patient (joint decision) or decision made by patient alone. The 
questionnaire was administered in the local Oshiwambo language which is the language spoken 
by the majority of patients in this clinic. 
2.8. Variables 
The variable that was measured in this study was the person who made the decision to 
commence anti-retroviral therapy. The frequency of each of the responses was quantified as a 
proportion of the total number of patients interviewed. While the true range of variation is 
infinite (since there are varying levels of involvement in the decision making process), the 
responses were categorized into three possible responses as discussed above; thereby making this 
a discreet variable.    
2.9.Pilot study        
This questionnaire was field-tested on 20 patients and was then refined based on the issues 
identified during the pilot study. Other operational and logistical issues were also fine-tuned 
during this pilot phase. 
2.10.Analysis 
The responses were categorized into the three possible categories and the frequency of each 
response was determined. This was then expressed as a percentage of the total number of patients 
interviewed; the responses were analysed by comparing the different frequencies of the 
responses. Data was double entered in Epidata 3.1 (210108) and analyzed using Epidata analysis 
V2.0.3.129. 
2.11.Ethical Aspects 
The patients were approached to participate in the interview during routine consultations when 
they presented for care in the clinic. The purpose of the interview was explained to the patients 
and the patients were asked to give verbal consent of their participation in the study. The 
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questionnaire was administered on those patients who consented to taking part in the study. No 
identifying details were obtained from the patients. The research was conducted as part of 
ongoing operational research for quality improvement at Oshakati Hospital and was thus exempt 
from the requirement of the full approval by the Research Committee in the Ministry of Health 
and Social Services.       
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3. RESULTS 
3.1. Demographic data 
A total of 266 patients were interviewed for the study. 7 of these patients were excluded from 
the analysis due to missing information. The 259 patients whose responses were analysed 
comprised of 171 females and 88 males. This represents a female to male ratio of almost 1.9:1 
which is probably a reflection of the patient population in this clinic. However this could also 
be due to the timing of the data collection since many of the men are seasonal workers who 
routinely migrate from Oshakati to go and work in the Southern part of the country. 
Furthermore this could also be a result of the lower health seeking behavior in males resulting 
in fewer of them being tested for HIV and put on treatment timely (discussed below). The mean 
age of the respondents was 40 years. 
Figure 3: Gender distribution of the study sample 
 
 
3.2. Proportion of patients involved in the decision making process 
It was hypothesized that 75% of patients were not part of the decision making process as far as 
the initiation of their anti-retroviral treatment was concerned. On the contrary however, as figure 
4 below shows; only 17% (95% CI, 12.5-21.5) of the patients responded that the decision for 
them to commence on ART had been taken exclusively by the health worker.  
Male
34%
Female
66%
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Figure 4: Chart showing the perceived decision maker to start HAART for both male and female patients 
 
The unexpected (yet desirable) outcome was that a significantly greater proportion of patients 
said they were part of the decision making process. 42% (95%CI, 36.1-47.9)said they decided on 
their own while 41% (95% CI, 35.1-46.9) said they made the decision together with a health 
worker. This means that overall, 83% (95% CI, 78.5-87.5) of the patients responded that they 
were involved to varying degrees in the decision to commence treatment. Using the Z-test for 
two proportions (http://www.dimensionresearch.com/resources/calculators/ztest.html) it was 
determined that there is a statistically significant difference between the hypothesized percentage 
of 75% and the actual finding that only 17% of the patients responded that they were not part of 
the decision to start treatment (Z-value=13.156 at 95% Confidence Interval). Thus the finding 
provides evidence for rejecting the scientific hypothesis that the majority of patients are not part 
of the decision to start ART. 
 
The above findings suggests that the GIPA principle is being implemented in Oshakati 
Communicable Disease Clinic. It should be noted that this can also be a result of social 
desirability bias since the questionnaires were administered by health care workers who work in 
the clinic and in a health care setting. Due to the stigma and difficulty associated with finding 
and interviewing PLHIV in the community, the health care setting was however the most 
feasible place to conduct these interviews.  
 
Health Worker
17% (95
% CI, 12.5-21.5)
Patient
42% (95%CI, 36.1-
47.9)
Health worker and 
patient
41% (95% CI, 35.1-
46.9)
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The advantages of having patient involvement in decisions concerning their treatment have been 
highlighted above. The ideal would therefore be to have all patients at least being involved to 
some extent in the decision concerning their treatment. It was noted by Beach C. M et al that 
“Compared to patients who prefer to share decisions with their HIV provider, patients who prefer 
that their provider make all/most decisions were significantly less likely to adhere to HAART…” 
(Beach, Duggan, & Moore, 2007). This emphasizes the need for collective decision making 
between the patient and the health care provider. 
 
3.3. Gender and the decision to start treatment 
 
Figure 5: Table showing proportions of by patients’ perceived decision makers to start ART by gender 
 
As shown in the table above and Figure 6 below there was remarkably little difference between 
males and females as far as the perceived decision maker for them to commence on ART was 
concerned. Although there was a significant difference in population size between males and 
females; this finding suggests that there is no major difference between males and females in 
their involvement in decisions regarding commencement of ART.  
 
 
 
 
 
 
Reported decision maker 
Proportions by gender (%)  
z-value (95% CI) Male Female 
Health Worker 17.4 18.1 0.028 
Patient 42.1 41.0 0.022 
Patient and Health Worker 40.5 41.0 -0.133 
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Figure 6: Chart showing the proportion of patients’ perceived decision maker (95% C I in brackets)
1
 
 
 
  
                                                          
1
 The confidence intervals were determined on the assumption that the gender proportion of the study sample 
was representative of the gender proportion of the study population. 
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4. LITERATURE REVIEW 
4.1. Introduction 
It is a well established fact that adherence to treatment is the cornerstone to optimal results with 
the currently available range of antiretroviral therapy (Johnson, et al., 2006). Conversely 
suboptimal adherence is the commonest reason for failure of anti-retroviral therapy and 
development of resistance to antiretroviral medicines. Operational research for antiretroviral 
therapy has therefore focused on trying to identify modifiable factors that can inhibit or facilitate 
adherence.  
4.2. Determinants of adherence to treatment  
According to (Konkle-Parker, Erlen, & Dubbert, 2008) there has been a lot of research into 
barriers to and facilitators for medication adherence for HIV infected individuals on 
antiretroviral therapy (ART). Barriers are usually classified into four main categories: 
 Patient related factors 
These are factors that depend on the patient and include factors such as literacy level, alcohol 
and substance abuse, health beliefs and depression and other psychiatric disorders. As can be 
noted many of these factors can be addressed by tailoring interventions to individual patients 
and making sure that the patient understands what they are supposed to do and that all co-
existing conditions are treated accordingly. Schneider et al also noted in a 2004 study that it 
is critical to determine and incorporate patients‟ belief systems about ART into adherence 
counselling sessions and to also screen for and treat psychiatric illnesses (Schneider, H, 
Greenfield, Li, & Wilson, 2004). This can be only if the individual patient‟s circumstances 
and belief systems are meticulously explored after establishing a trusting relationship with 
the patient. This reiterates the need for the active engagement of the patient in the entire 
treatment and care process. 
 Medication related factors 
These are factors related to the medicine itself and include side effects of the medicine, 
treatment complexity, number of pills as well as the dosage requirements for each medicine. 
The impact of medication related factors can be minimised if these are explained to the 
patient in advance and if the side effects are adequately treated. 
 Environmental factors 
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Environmental factors include beliefs of significant others, transportation and finances. 
Again these can only be understood and considered if the patient is assessed holistically and 
comprehensive intervention packages are implemented.  
 Provider related factors 
Provider related factors include such factors as communication and language, health worker 
attitude, clinic operational hours and accessibility of the health centres as well as the ability 
of the patient to participate in the decision making process. There are numerous studies that 
have been conducted directed at adherence issues for patients on antiretroviral therapy. There 
are however very few studies if any that have investigated the issue of relations between and 
health care providers and adherence to treatment (Johnson, et al.).  In a study published in 
2006, Johnson et al aimed “to explore a model of medication adherence in which the 
relationship between positive provider interactions and adherence is mediated by adherence 
self efficacy” using computerized self administered and interviewer administered self 
reported measures of medication adherence. They found that positive provider interactions 
may foster greater adherence self-efficacy among patients, which is associated with better 
adherence to medication. Patient-focused interventions that enhance self-efficacy may 
improve provider-patient interaction and lead to greater self-efficacy for medication 
adherence” (Johnson, et al.). Indeed the finding in this study suggest that there is significant 
patient involvement in major treatment decisions which can have a positive bearing on the 
patients‟ adherence to treatment. 
Jonson M.O et al therefore concluded that  
In a wide range of illness contexts, dimensions of patient satisfaction with providers' 
communication, engagement, and general interaction skills are linked to adherence to care. In HIV 
treatment, treatment plan adherence has been associated with patients' perceived level of 
engagement and satisfaction with their providers… For example, greater patient-physician 
agreement about top priority treatment strategies has been shown to predict greater self-efficacy 
for diabetes self-management (Johnson, et al.). 
It is for this reason that they postulated that training of health workers to increase collaborative 
negotiation with the patient in setting treatment goals and implementation of strategies to 
maximize the treatment outcomes is also likely to improve adherence self-efficacy and 
consequently improve the adherence itself. Patient-health care provider communication can also 
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improve adherence by allaying fears by patients about their condition, thereby reducing the stress 
associated with the disease (Johnson, et al.).  
 
In a study published in 2004, Schneider et al demonstrated that the nature of the doctor-patient 
relationship was associated with treatment adherence in PLHIV, suggesting that improving 
doctor-patient relationship quality can positively influence adherence to ART (Schneider, H, 
Greenfield, Li, & Wilson, 2004).  
“The belief that good physician-patient relationships are associated with better adherence to 
antiretroviral regimens for HIV infection is widespread, and supported by several qualitative 
studies…. Because accumulating evidence indicates that physicians‟ behaviors can be 
improved through training, targeting those specific aspects of the physician-patient 
relationship linked with greater adherence can serve to focus targeted, effective 
interventions…. Because of this, it is particularly important that providers understand every 
potentially modifiable risk factor for poor adherence” (Schneider, H, Greenfield, Li, & 
Wilson). 
 
The findings on the relationship between provider-patient relationships and adherence are 
however not uniform. In their study Konkle-Parker et al found no problems regarding the 
patient-provider relationship as a cause of poor adherence to treatment. They were however 
quick to note that as with the Oshakati study, the participants in this particular study were all 
from one clinic where recruitment for the focus groups occurred, and that the principal 
investigator was also from the same clinic. This might therefore have minimized willingness by 
the participants to mention negative feelings due to social desirability. The study however noted 
that support provided to patients by providers was a facilitator of adherence (Konkle-Parker, 
Erlen, & Dubbert, 2008). 
 
4.3. Gender and treatment adherence  
The gender dynamics associated with medication adherence need to be understood and accepted, 
and taken into consideration when designing interventions targeting patients of difference 
genders. The differences in health seeking behavior between males and females in different 
communities need to be acknowledged. Traditionally men tend to take longer to visit a health 
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facility when ill than females. A UNFPA paper noted this issue and advised that organisations 
and individuals “working with young men should be aware that they (young men) are not likely 
to seek health services, may see reproductive health as a women‟s concern, and are frequently 
misinformed” (UNFPA, Undated). Again it is important to take these factors into account when 
designing programmes addressing men. The current Namibian programme for the provision of 
ART does not distinctly specify these gender differences in the approach to patients despite it 
being generally agreed that men are taking longer to come to the HIV care clinics and that they 
are starting treatment when their CD4 count levels are lower compared to their female 
counterparts. 
 
Unfortunately many of the studies that have been carried out in this regard have been conducted 
in populations where the dynamics of the epidemic are very different for the sub-Saharan Africa 
situation. In Germany for example only 17% of the 59,000 PLHIV are female compared to sub-
Saharan Africa where the epidemic shows varying degrees of female predominance, and thus 
most of the clinical studies as well as cohort analyses have been conducted principally on HIV 
infected men. Harbel A. E et al noted in their study that there appears to be gender differences in 
the virological treatment outcomes between males and females. It is therefore important to 
consider and acknowledge these differences not only in behavior but in treatment outcomes as 
well (Haberl, S, Hanhoff, & Holm, 2008). This might even suggest that there are intrinsic 
differences between males and females which might require different levels of adherence to 
achieve the same levels of treatment success. These findings need to be validated in populations 
like in Namibia where the HIV infection tends to be more heterogeneous, with more females 
than males being HIV infected. 
 
While these gender differences have been acknowledged and reported in a number of treatment 
programmes, Applebaun J. A et al found no significant difference between the genders as far as 
the adherence levels were concerned. They however acknowledged that there is growing 
evidence of a discrepancy in adherence to ART between males and females possibly as a result 
of the different barriers to treatment faced by the different genders. In their study population they 
found that women living with HIV appeared to be particularly vulnerable to depressive 
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symptomatology which can potentially have a negative impact on adherence (Applebaum, 
Richardson, Brady, Brief, & Keane, 2009).  
 
Karina M. Berg et al also noted that a consistent relationship between gender and adherence has 
not been found, with several studies failing to show a significant association. They however 
noted that at the time they conducted their literature review there had been four published studies 
and five preliminary studies showing that women are less adherent than men. They also 
highlighted that the studies that showed no association between gender and adherence were 
limited either by small numbers of women or by the use of self-report as a measure of adherence; 
self-reporting has been shown to overestimate adherence. Their assessment of social and 
behavioural factors in their cohort of current and former opioid users showed that different social 
and behavioral factors are associated with adherence in men and women. “Among both men and 
women, worse adherence was associated with lack of long-term housing, not belonging to an 
HIV support group, crack/cocaine use, and medication side effects. Among women only, alcohol 
use was associated with worse adherence” (Berg, Demas, Howard, Schoenbaum, Gourevitch, & 
Arnsten, 2004). This was however in a specific population of former and current opioid users 
and can therefore not be taken to be representative of the general population. 
 
A different study sought to establish the intrinsic differences between men and women in their 
comprehension skills and assessed its potential impact on adherence. Waldrop-Valverde et al 
found that “women were less able than men to follow medication instructions and answer 
questions about (a) mock regimen” (Drenna Waldrop-Valverde). According to the authors of the 
study these findings highlight the differences in the skills used in managing medication regimens 
between men and women, and “suggest avenues to target for identification and intervention in 
medication management among women and men with HIV” (Drenna Waldrop-Valverde). The 
different health seeking behaviours of men and women was highlighted by Muula S. et al in 
2007 when they noted that  
(w)hile female to male HIV infection prevalence ratios in the southern African countries 
ranged from 1.2:1 to 1.6:1, female to male ratios on HAART ranged from 0.8: 1 to 2.3: 1 
with the majority of the reports having female: male ratio in treatment exceeding 1.6. 
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Overall, there were more females on HAART than there were males and this was not 
solely explained by the higher HIV prevalence among females compared to males 
As with the Oshakati study, they found that indeed there were proportionally more females on 
HIV antiretroviral treatment than men in Southern Africa even after accounting for the higher 
HIV infection prevalence in women. Even in the United States it has also been reported that 
women access HIV care earlier than men, with others reporting opposite findings (Muula, et al., 
2007). This accessibility seems to be reflected in the Namibian situation as well. This is thought 
to be due to the increased access facilitated by the testing of pregnant women for HIV during 
antenatal care as part of efforts aimed at prevention mother-to-child transmission of HIV. These 
differences suggest that interventions for treatment adherence cannot be uniform and are 
probably gender sensitive. It is therefore crucial to actively engage the patient in the treatment 
process and to make sure that the patient takes an active (if not leading) role in determining the 
direction of the ART. It is through such engagement that the patient‟s self efficacy is enhanced 
and the adherence to treatment is improved. 
4.4. The GIPA Principle     
The foregoing discussion has mainly focused on the provider-patient relationship as being able to 
facilitate or impair patients‟ adherence to treatment. One important factor is how well health care 
workers are responsive to the needs of the patients. This is important especially with medication 
adherence due to the limited measures that exist as far as trying to determine the true adherence 
to treatment is concerned. It is known that “clinicians tend to overestimate medication adherence, 
inadequately detect poor adherence, and may therefore miss important opportunities to intervene 
to improve antiretroviral adherence” (Miller, et al., 2002). Given this proven inability to predict 
or detect poor adherence it is imperative that health workers do what they can to try and facilitate 
adherence by maximising the facilitators and minimising the inhibitors of treatment of 
adherence. Responsiveness to patients‟ needs and including patients in the decision making 
process is one way of doing this. Taking into account the individuality of patients is another way 
of making sure patients adherence is facilitated.  
 
The Greater Involvement of People Living with HIV/AIDS (GIPA) has been advocated as the 
best way forward in designing programmes and interventions for PLHIV. According to 
Morolake et al GIPA “represents a mobilising and an organising principle for the involvement of 
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PLHIV in program and policy responses” (Morolake, Stephens, & Welbourn, 2009). They note 
however that governments and health systems have not yet fully harnessed the potential and 
resources of PLHIV in their efforts to fight the epidemic. (Morolake, Stephens, & Welbourn). 
They also noted that by its failure to take into account the specific and individual needs of 
PLHIV and through the negative experiences that PLHIV have had, the health care system has 
failed the majority of PLHIV and that health systems needed to be more responsive and had to 
adopt an “integrated approach …based on a human rights framework, grounded in community 
realities and delivered in partnership and solidarity with people living with HIV…” (Morolake, 
Stephens, & Welbourn). They further advocated for the development of a “proper people- 
centred not system-centred thinking and to create holistic projects which reflect real lives” 
(Morolake, Stephens, & Welbourn).  
 
Beach M. C et al also supported patient involvement in decision making in a study published in 
2007. Their literature review showed that patients who are more involved in their own medical 
care tended to have better treatment outcomes than those who left the decision making process 
entirely to their health care providers. They also noted that “23% of patients preferred that their 
doctor make all or most decisions, 63% preferred to share decisions with their doctor, and 13% 
preferred to make all final decisions alone”. However they also found in their study that those 
patients who preferred to make all the decisions on their own were less likely to adhere to their 
ART than those who preferred to make these decisions with the health care provider (Beach, 
Duggan, & Moore, 2007).  
“Studies have found that patients who report greater involvement in medical care are more satisfied 
with their physicians, report more understanding, reassurance, and perceived control over their illness 
and have improvements in medical conditions1. Furthermore, interventions to increase patient 
involvement have had beneficial effects on satisfaction and functional status, blood glucose (in 
diabetic patients), quality of life, and the frequency and length of hospitalizations …” (Beach, 
Duggan, & Moore). 
 
Patient involvement in care has not been as well studied among PLHIV but it needs to be borne 
in mind that HIV infection has received a lot of publicity. There are therefore bound to be a lot of 
misconceptions and myths brought about by this plethora of information and misinformation. 
Furthermore HIV treatment has a lot of options, hence the need to carefully engage the patient in 
25 
 
the selection of the treatment regimens. Because ART regimens require that the patient be 
adherent to avoid the development of resistance to the medication and the consequent disease 
progression, it is imperative for the patients themselves be fully committed to the treatment 
regimens (Beach, Duggan, & Moore). 
 
According to Martin R. L. et al “patient satisfaction and patient adherence are enhanced by 
patients‟ involvement and participation in their care” (Martin, Williams, Haskard, & DiMatteo, 
2005). They reiterated the finding that those patients with depression who actively participates in 
discussions of behavioral strategies as part of their treatment with their doctor are more likely to 
adhere to their antidepressant treatment and that “even when dealing with a serious illness such 
as cancer, most patients have been found to desire all possible information regarding their 
condition and treatment” (Martin, Williams, Haskard, & DiMatteo). For these reasons they 
concluded that “Participation, engagement, collaboration, negotiation, and sometimes 
compromise enhance opportunities for optimal therapy in which patients take responsibility for 
their part of the adherence equation” (Martin, Williams, Haskard, & DiMatteo).   
4.5. Summary 
Numerous studies have demonstrated that treatment outcomes for ART are strongly determined 
by the patient‟s adherence to treatment. This in turn is influenced by a number of factors which 
may be patient factors, medicine related factors, environmental factors and health worker related 
factors. Provider-patients relationships play a significant role in patients‟ adherence to treatment 
and most studies and authors advocate the active involvement of the patient in the decision 
making process and the designing of patients in their treatment. This is the main thrust of the 
GIPA principle. The extent of provider-patient concordance in the decision making process had 
not been well documented in Namibia, and it was not clear how well patients are involved in the 
decision making process as far as ART related decisions are concerned.        
  
4.6. Conclusion         
Based on the above information it was therefore necessary to establish the current levels of 
patient involvement in decision making process for ART in Namibia. This study therefore sought 
to find out what proportion of patients on ART perceived that they were part of the decision 
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making process when they started ART. It was found that a significant proportion of patients 
(83%) said that they were involved in the decision to commence treatment; and that there was no 
significant difference between males and females in their involvement in the decision to 
commence treatment. Whether the patients were actually involved in the decision making 
process or not could not be concluded from this study. This means that there is currently no 
evidence to suggest the need to modify the existing treatment protocols in Namibia. However, 
more research needs to be conducted in differenc settings to determine if the Oshakati findings 
are reflected nationally. Futhermore it woultd be useful to also conduct the study whereby the 
respondents are matched for gender for comparability purposes.  
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ANNEXES 
Annex 1: Questionnaire 
Unique ID. (Interviewers initials and sequential number: e.g. FM1, FM2, FM3, FM4 for 1,2,3,4 
etc 
Sex  M   F 
DOB 
Age (in years) 
By whom could you say; made the decision to start treatment? I will give you three answers and 
you choose the one that approximately describe your situation. 
1. The decision to initiate treatment was made by the health worker 
2. The decision to initiate treatment was made by the myself alone 
3. The decision to initiate treatment was made by myself and the health worker 
 
Annex 2: Electronic data capturing tool: Code book 
Field 
name 
Field Label 
Field 
type 
Field 
length 
Field Values Value labels 
UID Unique Patient ID Text  As recorded  
SEX Sex of the patient Number 1 
1 Male 
2 Female 
9 No sex indicated 
DOB Birth date of patient Date 10 
01/01/1920-
31/12/2007 
Exact date of birth 
01/01/1800 No date of birth recorded 
Age Age as recorded Number 3 
0-120 The age as recorded 
999 No age recorded 
Decision 
maker 
Who made decision Number 1 
1 Doctor/nurse 
2 Patient 
3 Patient and Health worker (s) 
69 Not indicated 
 
 
